Description: Kadcyla is a targeted anticancer medication designed to treat certain types of breast cancer. The active ingredient in Kadcyla is Trastuzumab Emtansine, a novel antibody-drug conjugate. It is supplied in the form of a sterile lyophilized powder for reconstitution and subsequent intravenous administration.

Uses: Kadcyla is indicated for the treatment of HER2-positive breast cancer in patients who have previously received trastuzumab and a taxane, separately or in combination. It is specifically employed in cases where the cancer has progressed despite prior treatments.

How to Use: Kadcyla is administered intravenously under the supervision of a qualified healthcare professional. The recommended dosage is usually determined by the patient’s body weight. The infusion process should follow the manufacturer’s guidelines, and patients should adhere to the prescribed treatment schedule.

Storage Conditions: The lyophilized powder should be stored in a cool, dry place, protected from light. Once reconstituted, the solution should be used immediately, or it can be stored in the refrigerator for a limited period as per the manufacturer’s instructions.

Mechanism of Action: Trastuzumab Emtansine is an antibody-drug conjugate that combines the anti-HER2 activity of trastuzumab with the cytotoxic properties of emtansine (DM1). The drug selectively delivers the cytotoxic agent to HER2-positive cancer cells, inhibiting their growth and promoting cell death.

Precautions:

• Patients should be monitored for signs of cardiac dysfunction, as trastuzumab has been associated with cardiotoxicity.
• Hepatic function should be assessed regularly, and dose adjustments may be necessary in case of hepatic impairment.
• Monitoring for infusion-related reactions and other potential adverse effects is essential.

Contraindications: Kadcyla is contraindicated in patients with a known hypersensitivity to trastuzumab or emtansine components.

Drug Interactions: There are limited documented drug interactions with Kadcyla. However, healthcare providers should be informed about all medications, including herbal supplements and over-the-counter drugs, that the patient is taking.

Side Effects: Common side effects of Kadcyla may include fatigue, nausea, musculoskeletal pain, thrombocytopenia, and elevated liver enzymes. Serious adverse reactions may include hepatotoxicity, interstitial lung disease, and cardiac dysfunction.

Patients should promptly report any unusual or severe side effects to their healthcare provider for appropriate management.

It’s important to note that the information provided here is a general overview, and specific details may vary. Patients should consult their healthcare professionals for personalized advice and information regarding Kadcyla.